CD274 and non-small cell lung carcinoma: For example, further insight into the potential utility of non-invasive PD-L1 assessment, within the context of radiotherapy, may come from an ongoing clinical trial of [89Zr]durvalumab in stage III NSCLC patients undergoing chemoradiation (ACTRN12621000171819) [32].